Cyclopropylamine LSD1 Inhibitors for Selective Enzyme Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with LSD1 activity, such as cancer, lack effective inhibitors that can selectively target and modulate lysine-specific demethylase-1 (LSD1), leading to inadequate therapeutic outcomes due to LSD1's role in regulating epigenetic marks and contributing to tumorigenesis and resistance to conventional therapies.
Innovation Solution
Development of compounds, specifically those of Formula I, which act as LSD1 inhibitors, capable of selectively modulating LSD1 activity, thereby inhibiting its enzymatic function and potentially combining with existing therapeutic drugs to treat LSD1-mediated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used to treat LSD1-mediated diseases, then treatment coverage is broad, but therapeutic effectiveness is insufficient due to inadequate LSD1 inhibition
Solution Approach 1:
The patent employs parameter changes by modifying molecular structure parameters of the compounds (Formula I) to optimize their binding affinity and inhibitory potency against LSD1. By adjusting structural parameters such as substituent groups on the core heterocyclic framework, the compounds achieve enhanced selective inhibition of LSD1 enzymatic activity, thereby improving therapeutic effectiveness while maintaining selective targeting capability
Solution Approach 2:
The patent introduces compounds of Formula I as intermediary substances that mediate between the therapeutic goal (LSD1 inhibition) and the biological system. These compounds act as molecular intermediaries that selectively bind to LSD1, blocking its demethylase activity and thereby translating the therapeutic intent into actual biochemical effect, resolving the contradiction between broad treatment coverage and selective targeting
2Reliability
If LSD1 inhibition is strongly targeted to improve therapeutic outcomes, then cancer cell proliferation is reduced, but potential off-target effects may increase
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features localized at key positions of the molecule. The core heterocyclic structure (pyridine, pyrimidine, triazine, etc.) with specific substituent patterns creates localized interaction zones that selectively engage LSD1's catalytic domain, enhancing inhibitory potency while minimizing interactions with off-target proteins, thus reducing potential harmful effects
Solution Approach 2:
The patent employs inversion by designing inhibitors that bind to the catalytic domain of LSD1 in a manner opposite to how substrates bind. Instead of facilitating the demethylase reaction, the compounds block the catalytic pocket, inverting the normal enzymatic function. This inverted binding mode achieves strong selective inhibition while the high specificity of the inverted interaction reduces off-target effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit LSD1, normalizing altered gene expressions, reducing cancer cell proliferation, and promoting apoptosis, offering a potential therapeutic benefit for LSD1-associated diseases by selectively targeting LSD1 activity.
Implementation Method 1
The compounds effectively inhibit LSD1, normalizing altered gene expressions
Data Source
AI summary
The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.